

Gary W Middleton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/332661/publications.pdf>

Version: 2024-02-01

93
papers

18,234
citations

47006
47
h-index

38395
95
g-index

97
all docs

97
docs citations

97
times ranked

26893
citing authors

#	ARTICLE	IF	CITATIONS
1	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. New England Journal of Medicine, 2008, 358, 36-46.	27.0	2,052
2	Tracking the Evolution of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	27.0	1,786
3	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	13.7	1,475
4	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	27.8	1,287
5	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	28.9	968
6	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet, The, 2020, 395, 1919-1926.	13.7	908
7	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	1.6	884
8	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 481-489.	10.7	631
9	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. Cancer Immunology Research, 2015, 3, 436-443.	3.4	631
10	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, The, 2014, 15, 78-86.	10.7	516
11	Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunology, Immunotherapy, 2011, 60, 1419-1430.	4.2	506
12	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncology, The, 2020, 21, 1309-1316.	10.7	473
13	Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	9.4	448
14	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell, 2018, 33, 649-663.e4.	16.8	448
15	Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, The, 2011, 377, 1749-1759.	13.7	362
16	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncology, The, 2013, 14, 749-759.	10.7	333
17	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	14.3	323
18	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	10.7	296

#	ARTICLE	IF	CITATIONS
19	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	10.7	293
20	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906.	5.6	185
21	First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1161-1170.	10.7	170
22	Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3786-3793.	1.6	155
23	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 1038.	4.3	154
24	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet</i> , The, 2016, 388, 1002-1011.	13.7	132
25	Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9) Tj ETQq1 1 0.784314 rgBT /Over Oncology, 2011, 29, 2667-2674.	1.6	128
26	Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1049-1057.	6.3	126
27	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	16.8	126
28	MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. <i>EBioMedicine</i> , 2019, 47, 235-246.	6.1	114
29	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 895-904.	10.7	111
30	KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 224-233.	7.0	101
31	Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 631-639.	10.7	97
32	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	27.8	96
33	An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. <i>OncoImmunology</i> , 2015, 4, e976052.	4.6	92
34	Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). <i>Journal of Clinical Oncology</i> , 2017, 35, 1506-1514.	1.6	92
35	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5315-5328.	7.0	81
36	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 175-183.	4.2	80

#	ARTICLE	IF	CITATIONS
37	Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.. Journal of Clinical Oncology, 1995, 13, 2317-2323.	1.6	78
38	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 2006, 94, 1107-1115.	6.4	71
39	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. British Journal of Cancer, 2004, 91, 1453-1458.	6.4	67
40	Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Annals of Oncology, 2013, 24, 702-709.	1.2	64
41	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	10.7	60
42	Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncology, The, 2022, 23, 748-757.	10.7	60
43	A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (Câ€VAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology, 1997, 97, 153-160.	2.5	58
44	The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of Oncology, 2015, 26, 2464-2469.	1.2	58
45	Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Nonâ€Small-Cell Lung Cancer: ERCC1 Trial (ET). Journal of Clinical Oncology, 2017, 35, 402-411.	1.6	54
46	The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19. Lancet Oncology, The, 2020, 21, 622-624.	10.7	53
47	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
48	Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Nonâ€Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1713-1721.	1.1	49
49	The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 325-342.	4.2	49
50	A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitorâ€Resistant Advanced Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 3023-3031.	1.6	42
51	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research, 2018, 24, 2859-2872.	7.0	40
52	<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	7.0	39
53	NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology, 2020, 9, 1845424.	4.6	38
54	Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Molecular Diagnosis and Therapy, 2020, 24, 339-349.	3.8	38

#	ARTICLE	IF	CITATIONS
55	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
56	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e220130.	5.9	34
57	COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. <i>European Journal of Cancer</i> , 2022, 175, 1-10.	2.8	34
58	Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1-7.	4.2	30
59	Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2004, 3, 235-242.	2.3	29
60	Symptomatic Control of Neuroendocrine Tumours with Everolimus. <i>Hormones and Cancer</i> , 2015, 6, 254-259.	4.9	29
61	New treatment options for advanced pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 673-696.	3.0	27
62	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	12.1	24
63	A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. <i>British Journal of Cancer</i> , 2022, 126, 238-246.	6.4	24
64	Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. <i>BMJ Open</i> , 2020, 10, e033009.	1.9	23
65	Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. <i>British Journal of Haematology</i> , 2022, 196, 892-901.	2.5	23
66	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). <i>European Journal of Cancer</i> , 2013, 49, 3507-3516.	2.8	21
67	Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. <i>Pathology and Oncology Research</i> , 2018, 24, 723-731.	1.9	21
68	Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2016, 114, 510-518.	6.4	17
69	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. <i>Nature Communications</i> , 2022, 13, .	12.8	17
70	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 563-571.	2.3	16
71	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1213-1222.	2.3	15
72	Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?. <i>British Journal of Cancer</i> , 2020, 123, 691-693.	6.4	15

#	ARTICLE	IF	CITATIONS
73	Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
74	Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 2018, 9, 36654-36665.	1.8	13
75	TGF- β 2 orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1583-1596.	4.2	12
76	Utility of COVID-19 Screening in Cancer Patients. Cancer Cell, 2020, 38, 306-307.	16.8	11
77	Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience, 2015, 2, 508-516.	2.2	11
78	Extended <i>RAS</i> Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist, 2021, 26, e261-e269.	3.7	10
79	Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. Oncotarget, 2020, 11, 3188-3197.	1.8	10
80	Metastatic rectal adenocarcinoma within haemorrhoids: a case report. Journal of Medical Case Reports, 2008, 2, 128.	0.8	7
81	Periodontal disease in a patient receiving Bevacizumab: a case report. Journal of Medical Case Reports, 2008, 2, 47.	0.8	7
82	Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. Journal of Pathology: Clinical Research, 2017, 3, 155-170.	3.0	7
83	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 2022, 19, 146-157.	1.6	7
84	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2012, 69, 815-824.	2.3	6
85	Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Current Medical Research and Opinion, 2018, 34, 865-871.	1.9	5
86	Investigating lymphadenopathy--report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital. Postgraduate Medical Journal, 2000, 76, 566-568.	1.8	4
87	A rare case of a retroperitoneal enterogenous cyst with in-situ adenocarcinoma. World Journal of Surgical Oncology, 2007, 5, 113.	1.9	4
88	Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma. Immunotherapy Advances, 2021, 1, .	3.0	4
89	Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.. Journal of Clinical Oncology, 2014, 32, 4121-4121.	1.6	4
90	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	3.1	4

#	ARTICLE	IF	CITATIONS
91	Characterising the impact of pneumonia on outcome in non-small cell lung cancer: identifying preventative strategies. Journal of Thoracic Disease, 2020, 12, 2236-2246.	1.4	3
92	Towards personalized treatment of smoking-related lung cancers. Nature, 2021, , .	27.8	1
93	A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates. Springer Proceedings in Mathematics and Statistics, 2019, , 125-133.	0.2	0